Form 4: Krystal Biotech Director Sells Shares After Option Exercise
Insider Transaction Report
Krystal Biotech Director Dino A. Rossi exercised stock options and subsequently sold an equal number of common shares under a Rule 10b5-1 plan.
Summary
- Dino A. Rossi, a Director of Krystal Biotech, Inc. (KRYS), reported transactions on February 19, 2026.
- Rossi acquired 18,950 shares of common stock by exercising stock options at a price of $8.79 per share.
- Immediately following the exercise, Rossi sold 8,116 shares of common stock at an average price of $260.4858 per share.
- Additionally, Rossi sold another 10,834 shares of common stock at an average price of $262.1 per share.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.
- Following these transactions, Rossi directly beneficially owns 78,691 shares of Krystal Biotech common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While a director sold shares, it was part of an option exercise and executed under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling.
Positives
- The exercise of stock options at a low strike price of $8.79 indicates a significant paper gain for the director.
- The transaction was executed under a Rule 10b5-1 plan, which suggests the sale was pre-scheduled and not based on immediate, non-public information.
Negatives
- The sale of 18,950 shares by a director reduces their direct ownership in the company.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider transactions, particularly sales, are often scrutinized by investors for potential signals regarding management's confidence in the company's future prospects. However, transactions executed under a Rule 10b5-1 plan are generally viewed as less indicative of immediate sentiment, as they are pre-scheduled.
Stakeholder Impact
- Shareholders may observe the director's reduction in direct share ownership, though the Rule 10b5-1 plan context is important for interpretation.
Key Dates
| Date | Description |
|---|---|
| 06/01/2018 | Start date for the four-year vesting period of the stock options. |
| 02/19/2026 | Date of stock option exercise and subsequent sale of common stock. |
| 05/31/2027 | Expiration date of the exercised stock options. |
Keywords
Krystal Biotech, KRYS, Insider Trading, Form 4, Stock Options, Director, Share Sale, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.